Business

Biogen Advances Alzheimer's Drug to Late-Stage Trial

Updated 2026-05-14 16:35 UTC 1 source Positive

Biogen has advanced its Alzheimer's drug to late-stage clinical trials, despite initial disappointing data. The treatment shows promise in reducing tau levels and slowing cognitive decline.

Coverage timeline — 1 article

CNBC

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

2026-05-14 16:10 UTC